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Many studies have been done to evaluate the effect of various natural products in controlling asthma symptoms. Virgin coconut
oil (VCO) is known to contain active compounds that have beneficial effects on human health and diseases. The objective of this
study was to evaluate the effect of VCO inhalation on airway remodelling in a rabbit model of allergic asthma. The effects of VCO
inhalation on infiltration of airway inflammatory cells, airway structures, goblet cell hyperplasia, and cell proliferation following
ovalbumin induction were evaluated. Allergic asthma was induced by a combination of ovalbumin and alum injection and/or
followed by ovalbumin inhalation.The effect ofVCO inhalationwas then evaluated via the rescue or the preventive route. Percentage
of inflammatory cells infiltration, thickness of epithelium and mucosa regions, and the numbers of goblet and proliferative cells
were reduced in the rescue group but not in preventive group. Analysis using a gas chromatography-mass spectrometry found that
lauric acid and capric acid were among the most abundant fatty acids present in the sample. Significant improvement was observed
in rescue route in alleviating the asthma symptoms, which indicates the VCO was able to relieve asthma-related symptoms more
than preventing the onset of asthma.
1. Introduction
Asthma is an airway disorder that is characterised by a
specific pattern of inflammation that is largely driven by
immunoglobulin E-dependent mechanisms in the airway
[1]. Asthma onset can be triggered by internal and external
factors, including environmental allergens, stress, cigarette
smoke, and changes in weather [2, 3]. In airway remodelling
of asthma, a number of changes occur, including epithelial
goblet cell hyperplasia and metaplasia, collagen deposition
and thickening of the lamina reticularis, smooth muscle
hyperplasia, and proliferation of airway blood vessels [4].
Many researchers have studied the antiasthmatic and
anti-inflammatory effects of several plant-based therapies,
including thymoquinone from the seed of Nigella sativa, and
the crepe myrtle (Lagerstroemia indica) on animal models
of chronic and acute airway inflammation [5–9]. Yang et
al. (2008) studied the effect of an extract of Duchesnea
chrysantha on leukocyte infiltration and mucous secretion
and reported that the extract reduced inflammation due to
leukocyte infiltration andmucous hyperproduction by goblet
cells [10].
VCO has been studied extensively because the free fatty
acids in this oil have beneficial effects on many aspects of
human health and disease such as antibacterial, antiviral,
anti-HIV, anti-inflammatory, and antidiabetic properties [11–
13]. Other than that, anticancer properties of the VCO have
been reported by Kamalaldin et al. (2015) where the VCO
was able to induce apoptosis on lung cancer cell and gave no
toxic effect towards normal fibroblast cell [14]. The VCO is
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extensively used as a topical application to treat skin disorders
[15]. The efficacy and safety of VCO in reducing visceral
adiposity indicate that VCO is efficacious in weight reduction
and is safe for human consumption [16]. To provide scientific-
based evidence to support anecdotal claims, this study was
designed to evaluate the effect of VCO inhalation on airway
remodelling in a rabbit model of allergic asthma.
2. Materials and Methods
All chemicals used in this study were of analytical grade
andwere purchased fromSigma-Aldrich (Munich,Germany)
unless stated otherwise.
2.1. Virgin Coconut Oil. The VCO sample was obtained from
Nutrifera (Kelantan Biotech Corp Sdn. Bhd., Kota Bharu,
Malaysia).
2.2. Development of the Chronic Lung Injury Model. Male
New Zealand white rabbits (𝑛 = 25) weighing 2.60 ± 0.38 kg
were used in this study. The study was approved by
The Animal Research Ethics Committee of USM (JEHUSM)
(USM/Animal Ethics Approval/2012/(77)(379)). The rabbits
weremaintained in a ventilated roomand fed daily withwater
and pellets. The rabbits were divided into five groups (𝑛 = 5
each): (1) negative control (naı¨ve group), (2) i.p. ovalbumin
(OVA) control, (3) OVA inhalation control, (4) VCO as a
rescue agent, and (5) VCO as a preventive agent. Groups (2)
and (3) were later combined into the OVA-induced injury
group. Figure 1 shows the timeline for treatment in each
group.
2.3. Sample Collection. Blood, bronchioalveolar lavage (BAL)
fluid, and lung were collected for whole blood count
(WBC) and inflammatory cell staining. The rabbits were first
anesthetised using ketamine (35mg/kg) and ilium xylazyl
(4mg/kg) via intramuscular injection and blood was col-
lected. Following blood collection, the BAL fluid from each
rabbit was collected by lavaging the lung via the trachea with
3ml of phosphate buffered saline (PBS) twice. The collected
BAL fluid was centrifuged at 400 xg for 5min at 4∘C. The
supernatant was stored at −70∘C for later use. The pellet
was used for inflammatory cell staining. The lung collected
was according to standard protocol for tissue processing and
embedding.The processed tissue blocks were proceeded with
embedding process and then sectioned into 5 𝜇m thick slices
using a microtome. The tissue ribbons were collected, placed
on normal and polysine-coated slides, and air-dried prior to
histological analysis.
2.4. Histological Analysis. The tissue ribbons on normal and
polysine-coated slides as well as cytospun cells from BAL
fluid were used for histological analysis. Wright-Giemsa
staining, hematoxylin and eosin (H&E) staining, and alcian
blue-periodic acid Schiff (AB-PAS) staining were performed
following standard staining procedures.
Immunohistochemical (IHC) staining for PCNA marker
was conducted following the manufacturer’s protocol of the
DAKOARK Peroxidase kit (DAKOARKPeroxidase, Dako,
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Figure 1: Experimental design used in this study.The control group
serve as negative control; meanwhile OVA-induced injury group
serve as positive control for lung injury. Treatment groups were the
VCO as a rescue agent group and VCO as a preventive agent group.
Adapted and modified from Kumar et al. (2008) and Kamaruzaman
et al. (2014) [17, 18].
Glostrup, Denmark). In this study, 250𝜇L of primary anti-
body cocktail, which contained anti-PCNA antibody (PC10)
(proliferation marker, prediluted ab912, Abcam, Cambridge,
MA, USA), biotinyl reagent (DAKOARKPeroxidase), block-
ing reagent (DAKO ARK Peroxidase), and antibody diluent
(DAKO ARK), was used. Streptavidin-HRP (DAKO ARK
Peroxidase) was used as the secondary antibody.
2.5. Statistical Analysis. All data were expressed as the mean
± standard deviation (SD) of triplicate analyses. Statistical
differences among the data collected were determined with
two-sided Kolmogorov-Smirnov independent nonparamet-
ric tests using SPSS 20. 𝑝 ≤ 0.05 was considered to be
statistically significant.
2.6. Fatty Acid Content of VCO
(a) Preparation of Crude Extract. The extraction of fatty acids
from the VCOwas carried out using ethanol as the solvent in
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Figure 2: Haemorrhage areas on the sensitized lung, represented
by circle. (a) Control; (b) OVA-induced injury; (c) VCO as a rescue
agent group; (d) VCO as a preventive agent group. In the OVA-
induced injury group (b), the rabbits were injected with OVA
together with alum, which acts as an adjuvant; later, some were
exposed to repeated inhalation of OVA. Rabbits were given VCO
via nasal inhalation for 5 days. The degree of inflammation of the
lung (black circle) was observed following the sensitization stage
using i.p. OVA and inhalation of OVA.The haemorrhage areas were
reduced in both treatment groups (rescue (c) and preventive (d)),
especially in the rescue group.
a 1 : 10 (v/v) sample to solvent ratio. The extract pellets were
dissolved in methanol as the solvent carrier to be used in the
GC-MS analysis.
(b) Gas Chromatography-Mass Spectrometry (GC-MS). The
VCO crude extracts were diluted to 10mg/ml with ethanol.
Quantitative GC-MS analysis was performed using Agilent
5975C GC/MSD, an automated gas chromatograph system
(Agilent Technologies, CA, USA). In this analysis, the VCO
extracts were introduced by thermal desorption and split
injection at 250∘C at 10 : 1 into a HP5-MS column with 30m
× 0.25mm i.d. and film thickness of 0.25 𝜇m. The split flow
wasmaintained at 8ml/min.The carrier gas, helium,was kept
at a constant flow rate of 3ml/min. The oven temperature
program was set as follows: 70∘C for 2min, 5∘C/min increase
to 250∘C for 10min, and hold at 300∘C for 45min. The
temperature of the ionization chamber was set at 250∘C, and
the ionization stage was performed by electron impact at
70 eV. The detected peaks were identified by comparing the
retention time andmass spectrawith themass spectral library
in the online mass spectral database from National Institute
of Standard and Technology (NIST05). All matches above 0.9
were selected in this study.
3. Results
3.1. Development of the Allergic Asthma Model. The allergic
asthma model was developed by exposing rabbits to OVA
with aluminium (alum) hydroxide via i.p. injection and OVA
inhalation. In the OVA inhalation group, the i.p. injection
was followed by inhalation of OVA. The injury in the lungs
was detectable during postmortem as signs of lung haemor-
rhage, which was observed following allergen sensitization
(Figure 2).
The development of allergic asthma in the animal model
was illustrated by structural changes of the airway (epithe-
lium, mucosa, and submucosa; Figure 3(a)). The observed
changes included epithelium thickness and disruption of the
epithelial structure, and infiltration of inflammatory cells into
the airway lumen (Figure 3(d)(B)). Morphometric analyses
have shown significant changes on the airway structures of
the injury model as compared to the control group: the
thickness of the epithelium (41.6277 ± 1.7245 (𝑝 = 0.000)),
mucosa (46.3162 ± 1.7054 (𝑝 = 0.000)), and submucosa
(107.6487 ± 6.1114 (𝑝 = 0.000)) in the OVA-induced injury
group (Figure 3(c)).
Mucous oversecretion represented by the goblet cell
hyperplasia was also observed in the OVA-induced injury
group (Figure 4(a)(B)). Following induction using OVA and
alum, the numbers of mucous-producing cells, the goblet
cells, were significantly increased (𝑝 < 0.05) in the injury
group relative to the control group (Figures 4(b) and 4(c)).
Goblet cell hyperplasia, the important feature in asthmatic
airways, was well developed in this study (Figure 4(a)(A)
versus Figure 4(a)(B)), indicating the development of airway
inflammation in this model.
3.2. Effect of VCO Inhalation on the Animal Model of Allergic
Asthma. During postmortem, the lung haemorrhage was
observed in the OVA-induced injury group, VCO as a
rescue agent group (Figure 1(c)), and VCO as a preventive
agent group (Figure 1(d)). Following injury, the animals were
exposed to VCO inhalation as a rescue agent (28 d time
point) or a preventive agent (31 d time point). After VCO
inhalation, haemorrhage severity in the lungs was reduced in
both treatment groups, but better reduction was observed in
the rescue group (Figure 2; VCO as rescue agent).
The different types of inflammatory cells were identi-
fied by different levels of cytoplasmic granularity and the
morphology of the nucleus. The total cell count (expressed
as percentage of cells) showed that the numbers of proin-
flammatory cells (eosinophils and basophils) were high in
the OVA-induced injury group (1.29% ± 1.26% and 2.46%
± 2.79%, resp., Figure 4(b)), indicating that injury had
developed in the animal model. Treatment with VCO did not
significantly reduce the total cell count for proinflammatory
cells, but the mean values for eosinophils and basophils were
reduced in the VCO as a rescue agent group (0.63 ± 0.34 and
1.97 ± 2.82, resp.) but not in the VCO as a preventive agent
group (1.21 ± 0.96 and 4.61 ± 6.08, resp.). In the VCO as a
rescue group, the neutrophil count was increased (66.79 ±
11.79) but the lymphocyte count was decreased (28.63 ±
12.10) relative to the OVA-induced injury group. However,
the monocyte count for the rescue group was comparable to
that of the control group. Although differences were observed
for cell count between each treatment group, the differences
were not statistically significant except for lymphocytes and
monocytes (Figure 5(b)).
H&E stained lung sections showed structural differ-
ences between the injury (Figure 3(d)(B)) and treatment
groups (Figure 3(d)(C and D)) compared to control ani-
mals (Figure 3(d)(A)). In the OVA-induced injury group
4 International Journal of Inflammation
(d)
(C)
(B)
(D)
(A)
400x
SMC
E
L
400x
IE
SM
C
L
400x
IE
ESM
L
400x
IE
ESM
L
Epithelium Mucosa
Submucosa
BM
SM
C
SM SM
(a)
(c)
Group
Epithelium Mucosa Submucosa
Control animal
OVA-induced injury
VCO as rescue agent
VCO as preventive agent
aSignificant against control animal group, bsignificant against injury group, cnot
significant against control animal group, and dnot significant against injury group.
30.82 ± 1.20
41.63 ± 1.72a
35.71 ± 2.35b,c
43.57 ± 2.69a,d
33.29 ± 1.20
46.32 ± 1.71a
38.93 ± 2.30b,c
46.54 ± 2.70a,d
74.50 ± 3.59
107.65 ± 6.11a
117.31 ± 9.64a,b
112.00 ± 7.17a,d
0.000
0.000
0.006
0.000
0.000
0.001
Treatment group
(b)
0.000
0.0340.000
Th
ic
kn
es
s(
𝜇
m
)
0.00
100.00
200.00
300.00
400.00
500.00
Su
bm
uc
os
a
0.00
20.00
40.00
60.00
80.00
100.00
120.00
M
uc
os
a 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
Ep
ith
el
iu
m
 
RescueInjury PreventiveControl
Injury Rescue PreventiveControl
Injury Rescue PreventiveControl
Measurement, 𝜇m (Mean ± S.D)
Figure 3: Structural changes of the airway. (a) Illustration of the epithelium, mucosa, and submucosa measurement area for H&E stained
slides. The mucosa area ranges from the epithelial cell to the end of the basement membrane (BM). The submucosa area ranges from
the smooth muscle (SM) to the end of the cartilage (C). The measurements were in microns (𝜇m). (b) Thickness measurements of
airway structures. The boxplot shows the measurements (mean ± SD) made for three parameters: epithelium, mucosa, and submucosa. (c)
Morphometric analysis of airway structure of airway lumen. The data were subjected to the two-sided nonparametric analysis using SPSS
software. The outliers represent high and low data readings. 𝑝 < 0.05 was considered to be statistically significant. (d) H&E staining for
each treatment group. (A) Control, (B) OVA-induced injury, (C) VCO as a rescue agent, and (D) VCO as a preventive agent. Following OVA
inhalation, the epithelium (E) was thicker as compared to the control animal. Infiltration of inflammatory cells (I) was also found in the airway
lumen (L), indicating that the injury was developed. Following VCO inhalation, airway remodelling (epithelium, mucosa, and submucosa
structure) was reduced compared to the OVA-induced injury group. I, inflammatory cell infiltration; E, epithelium; SM, smooth muscle; C,
cartilage; L, airway lumen.
(Figure 3(d)(B)), the arrangement of the epithelium and the
structure of the mucosa layer were disrupted, and infiltration
of inflammatory cells into the airway lumen was observed.
This observation supported the findings of themorphometric
analysis, which showed significant differences (𝑝 < 0.05) in
all structures between injury and control animals.
After treatment with VCO, the morphometric analysis
revealed significant differences between the injury and the
VCO as a rescue group for epithelium thickness (35.71 𝜇m
± 2.35 𝜇m, 𝑝 = 0.034) and mucosa thickness (38.93 𝜇m
± 2.30 𝜇m, 𝑝 = 0.006) but not for submucosa thickness
(117.31 𝜇m ± 9.64 𝜇m, 𝑝 = 0.689). However, no signifi-
cant differences for any parameter measured were detected
between the injury and the VCO as a preventive agent group
(Figure 3(b)).
AB-PAS staining revealed that goblet cells were abundant
in the OVA-induced injury group (21.90 ± 10.49%) (Fig-
ure 4(a)(B)) compared to the control group (5.64 ± 4.13%)
(Figure 4(a)(A)). After inhalation of VCO, the goblet cells
were sparsely observed in the VCO as a rescue agent group
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Figure 4: Staining of goblet cells. (a): (A) Control, (B) OVA-induced injury, (C) VCO as a rescue agent, and (D) VCO as preventive agent
groups. Goblet cells (black arrow) present in all treatment groups but at different densities. Positive staining for goblet cells are indicated by
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Morphometric analysis of the goblet cells in each treatment group revealed significant differences between control animals and the OVA-
induced injury group (𝑝 = 0.000), control animals versus the VCO as a preventive agent group (𝑝 = 0.000), and OVA-induced injury versus
VCO as a rescue agent group (𝑝 = 0.001). (c) Morphometric analysis of the goblet cell counts. 𝑝 < 0.05 was considered to be statistically
significant.
(11.01 ± 9.98%). However, the goblet cell count in the VCO
as a preventive agent group (20.65 ± 14.53%) was similar to
that of the OVA-induced injury group. Overall, significant
differences were observed between the control and OVA-
induced injury groups (𝑝 = 0.000), the control and VCO as
a preventive agent group (𝑝 = 0.000), and the OVA-induced
injury and VCO as a rescue agent group (𝑝 = 0.000). The
number of goblet cells did not differ significantly between
the VCO as a rescue agent group and the control group
(Figure 4(c)).
In this study, proliferation of the airway cells was
observed during the repair process. Positively PCNA-stained
cells were infrequently found in the control animal tissue
(Figure 6(a), lower panel), and those present were mostly
found among alveolar cells. After exposure to the injury
agent, proliferative cells become abundant, indicating that
the cells were actively dividing and proliferating in order
to combat infiltration of the sensitizer (i.e., OVA). The cells
were observed at the basal area of the epithelium and smooth
muscle and among alveolar cells (Figure 6(b), lower panel).
After treatment with VCO, the positive-stained cells were
distributed among the airway epithelial and cell infiltrates
in the submucosa area (Figures 6(c) and 6(d), lower panel).
However, the number of proliferative cells in the VCO as a
rescue agent group was lower among the cell infiltrates and
alveolar area compared to that of the VCO as a preventive
agent group (Figure 6(c), lower panel).
3.3. Fatty Acid Content of VCO. GC-MS analysis revealed
the presence of 17 compounds in the VCO extract. Most of
the volatile compounds detected consisted of free fatty acids,
methyl groups, benzene groups, and traces of metals. The
dominant peak (total peak area ∼ 40.86%) was a 12-carbon
compound known as dodecanoic acid (i.e., lauric acid)
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Figure 5: The infiltration of inflammatory cells in different groups. (a) Different types of inflammatory cells were observed in BAL fluid
from different treatment groups: (A) Control, (B) OVA-induced injury, (C) VCO as a rescue agent, and (D) VCO as a preventive agent.
The distributions of the inflammatory cells differed among groups. M, mast cell; Eo, eosinophil. (b) Results of whole blood cell screening.
Abundance of different cell types is expressed in percentage (%) of the total cell count. 𝑝 < 0.05 was considered to be statistically significant.
(Table 1). The percentage of the peak area (% area) represents
the percentage of a given compound among the total com-
pounds in the VCO sample.
4. Discussion
In animal models of chronic lung injury, ovalbumin, which is
a protein from chicken eggs, frequently is used as an allergen.
This substance can induce robust, allergic pulmonary inflam-
mation in laboratory rodents [19]. In studies focused on the
action of inflammatory cells, OVA with the addition of alum
was used to elicit an immune response, thereby mimicking
airway inflammation condition in humans [6, 20–23]. During
the sensitization stage, alum acts as an adjuvant that can
enhance the action of OVA against the defence systems of
the body [21, 23–26]. The addition of alum during injection
of OVA not only induces but also increases the production
of inflammatory cells, especially Th
2
, Th
1
, IL4, and IL5 [25].
The use of alum in inducing chronic lung injury, especially
asthma, has been well established and widely used in rat,
mouse, and rabbit models [24, 26–28].
In the current study, the injured area of the lung was
detected by the presence of haemorrhage, which was caused
mainly by repeated exposure to the allergen (OVA and alum).
Severe haemorrhage was observed in lung samples from
the OVA-induced injury group. This condition was reflected
by high infiltration of inflammatory cells in the BAL fluid.
Eosinophils are the most prominent inflammatory cells in
asthma, and theymay be amediator for the epithelial damage
that occurs during asthma pathogenesis [29, 30]. Other
common features of airway injury in asthma are remodelling
of the airway structures, which includes epithelial damage,
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Figure 6: Distribution of PCNA-stained cells in all treatment groups.The actively proliferating cells are stainedwith PCNA. Positively stained
cells can be identified by the deep brownnuclei. In control animals (a), positively stained cells are infrequent among the alveolar cells. Exposure
to the allergen (OVA and alum) increased the number of positively stained cells in the injury group (b), indicating that the cells are actively
dividing and proliferating to combat infiltration of the sensitizer into the lung. The cells are observed at the basal area of the epithelium (E),
smooth muscle (SM), and alveolar cells. After treatment with VCO, positively stained cells are also observed among the airway epithelial cells
and cell infiltrates in the submucosa area (c and d). C, cartilage.
Table 1: List of free fatty acids detected in the VCO sample.
IUPAC Common name Lipid number Molecular formula Percentage of composition (%)
Dodecanoic acid Lauric acid C12:0 C
12
H
24
O
2
40.86
Methyl tetradecanoate Methyl myristate C15:0 C
15
H
30
O
2
11.14
Octanoic acid Caprylic acid C8:0 C
18
H
16
O
2
7.69
Decanoic acid Capric acid C10:0 C
10
H
20
O
2
5.17
Hexadecanoic acid Palmitic acid C16:0 C
16
H
32
O
2
4.22
9-Octadecenoic acid Oleic acid C18:1 n-9 C
18
H
34
O
2
0.33
The IUPACnomenclaturewas referred as InternationalUnion of Pure andAppliedChemistry. All the compounds listedwere selected based on the 0.9matching
with the National Institute of Standard and Technology (NIST) database.
increased airway smoothmuscle, mucous gland hypertrophy,
and goblet cell hyperplasia [31–34]. These injury features
limit airway function by thickening the airway wall and
narrowing the airway lumen, thus reducing the airway flow
rate; these processes most likely are due to eosinophilic and
neutrophilic infiltration across the alveolar wall into the
alveolar spaces [35–38]. Thickening of the airway smooth
muscle, inflammatory cell infiltration into the alveolar spaces
and lamina propria layer, epithelial hypertrophy, and goblet
cell hyperplasia were all observed in the OVA-induced injury
group but not in the control group (Figures 3, 4, and 5). This
cellular response proved that the rabbit model for an allergic
airway inflammation was well developed prior to treatment
with VCO inhalation, at least for some features that mimic
human condition of asthma.
The main objective of this study was to evaluate the
anti-inflammatory effects of VCO in reducing asthma-related
features (i.e., infiltration of inflammatory cells, remodelling
of airway structure, and goblet cell hyperplasia). The effect of
VCO inhalation was measured by its ability to eliminate the
inflammatory cells, including eosinophils, which are known
to play an important role in the pathogenesis of airway
disorders [39]. Our findings showed that VCO inhalationwas
effective at alleviating the inflammatory responses in the air-
way, but the response was more profound in the rescue group
than in the preventive group. Anti-inflammatory effect of the
VCO has been reported by Intahphuak et al. (2010) where,
in acute inflammatory models of ethyl phenylpropiolate-
induced ear edema in rat, the VCO treatment gave moderate
anti-inflammatory effect. The VCO was also found to be
able to reduce the transudative weight, granuloma formation,
and serum ALP activity [13]. Another finding on anti-
inflammatory effect of the VCO also has been recorded by
Zakaria et al. (2011).The study stated that the VCOs exhibited
anti-inflammatory activity in an acute (carrageenan-induced
paw edema test), but not in a chronic (cotton-pellet-induced
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granuloma test) model of inflammation [40]. In both groups,
the number of eosinophils was reduced relative to the OVA-
induced injury group, and the reduction pattern was similar
for other types of inflammatory cells (i.e., lymphocytes,
monocytes, and basophils). Reduction in the inflammatory
cell counts was also reflected by the structural changes of
the airway, as the infiltration of inflammatory cells led to
remodelling of airway structures (epithelium, mucosa, and
submucosa). In the VCO as a rescue agent group, epithelium
and mucosa thickness was significantly reduced compared to
that of the OVA-induced injury group. However, these mea-
surements did not differ significantly between the preventive
group and the OVA-induced injury group, which might be
due to the repeated inhalation of OVA after VCO inhalation
(days 28, 29, and 30) that might have stimulated continuous
infiltration of inflammatory cells.
In the healthy airway, the main function of mucin is to
maintain the sterility of the lower airspace by trapping foreign
particles in the upper airways [41]. The secretion of mucin is
also crucial for humidifying the alveolar surface for optimum
gaseous exchange in the lung. However, overproduction
of mucin (or mucous hypersecretion) due to goblet cell
hyperplasia triggered by the infiltration of pathogens into the
lung spaces leads to increased severity of asthma. The model
of allergic airway in the current study was successfully devel-
oped, in which some features mimic human conditions of
asthma, as indicated bymucous overproduction due to goblet
cell hyperplasia in the OVA-induced injury group. Extensive
studies conducted by several researchers have documented
direct involvement of goblet cell hyperplasia in the severity
of asthma pathogenesis [34, 42–44]. Ordon˜ez et al. (2001)
reported that the chronic narrowing of the airway lumen in
moderate and mild asthma was mainly caused by the accu-
mulation of mucus along the airway [44]. In addition, Dong
et al. (2012) reported that activation of goblet cell hyperplasia
is closely related to infiltration of eosinophils into the airway
lumen during the sensitization stage [45]. Inhalation of VCO
resulted in a significant reduction of goblet cells hyperplasia,
especially in the VCO as a rescue agent group. This might be
due to the action of anti-inflammatory effects of VCO that
facilitates in reducing the severity of the mucous secretion
after allergen sensitization. Thus, this finding indicates that,
by reducing the inflammatory cell responses due to ova
induction, the inhalation of VCO also reduced the goblet cell
hyperplasia (i.e., mucous overproduction) in this model of
airway inflammation. Behind the pathogenesis of the mucus
overproduction and goblet cell hyperplasia, most prominent
genes that contribute to these asthma characteristics are
the A Disintegrin And Metalloproteinases (ADAMs) and
ADAM with Thrombospondin (ADAMTS), and the aqua-
porin family [45–47]. A significant regulation of this gene
might be one of the possible answers for the effectiveness of
our treatment on animal model. Further study to elucidate
the molecular regulation of mucus-secreting related genes
is important as to determine the mechanisms on how the
VCO controls the overproduction of mucus and goblet cell
hyperplasia in a model of allergic asthma. The genes that
can be evaluated further are Th2-related genes (interleukin
4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13)),
transforming growth factor-𝛽 (TGF-𝛽), mucin (MUC) genes
(MUC5AC, MUC5B), Signal Transducer and Activator of
Transcription 6 (STAT6), and forkhead box A2 (FOXA2)
which are closely involved in asthma onset and progression.
The infiltration of active inflammatory cells during an
allergen attack in the lungs leads to hypertrophy of smooth
muscle cells and epithelial cells, which subsequently leads
to airway remodelling, which in turn narrows the airway
lumen [4, 48, 49]. Increase in the number of proliferation
activity of the airway epithelial cells in response to allergen
induction to the airway was supported by the high numbers
of PCNA-stained cells in the OVA-induced injury group.
Following treatment with VCO, fewer PCNA-positive cells
were present in the VCO in a rescue group but not in
the VCO as a preventive group. This finding correlates
with the infiltration of inflammatory cells (Figure 5(b))
and airway structure remodelling (Figures 3(c) and 3(d))
results where fewer proinflammatory cells were found and
reduction in epithelium andmucosa thicknesses in the rescue
group (Figure 3(c)). The difference between the rescue and
preventive agent groups (i.e., a series of repeated inhalations
ofOVAbefore the sampleswere collected) explains this result.
Repeated inhalation of an allergen increases the infiltration
of inflammatory cells into the area of injury, thus leading to
greater severity of asthma pathogenesis. The involvement of
inflammatory cells during injury activates cell proliferation,
which is required to repair the injury. Activation of PCNA
is associated with active replication and reparation of DNA
during the cell cycle [50–52].
Repeated inhalation of OVA following treatment with
VCO in the preventive group was used to determine if
VCO can be used to replace long-acting-beta-2 agonists
(LABAs, preventive drugs) or only to replace short-acting-
beta-2 agonists (SABAs, rescue drug) in current asthma
treatment. We found that reexposure to the allergen (OVA)
in the preventive group increased the infiltration of proin-
flammatory cells (eosinophils and basophils) into the area of
injury (Figure 5(b)). We believe that this was the main reason
why VCO acted better as a rescue agent than a preventive
agent.
Several drugs are available for quick relief during asthma
attacks. However, due to the long-term side effects of pro-
longed usage of these drugs, natural products are becoming
the focus of studies designed to discover complementary and
alternative treatments. Natural products are well known for
their high antioxidant content and their ability to replace
conventional drugs for therapy. ExtractingVCO frommature
fresh coconut meat can be performed using wet or dry
methods [12, 53]. In this study, a wet method was employed,
which involved chilling and thawing processes. Both low
(5∘C) and high (25∘C) temperature were used to destabilize
the coconut milk emulsion in order to extract the oil from
the oil globules in the chilled coconut milk [54]. Previous
studies evaluated different methods for production of VCO
and reported that themost favourablemethods for producing
VCO with high fatty acid and oil recovery were the chilling
and thawing method and the enzymatic method [54–56].
Since our interest was to know what might be the main
compounds contributing to the anti-inflammatory effects of
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VCO inhalation, the VCO was then screened for possible
antioxidant, anti-inflammatory, and antiasthmatic compo-
nents using GC-MS technology. GC-MS analysis revealed the
presence of 17 volatile organic compounds from themethanol
extracts of the VCO. Lauric acid was the main medium-
chain triglyceride present in the VCO, and it represented
40.86% of the total content. The Asian and Pacific Coconut
Community (APCC) standard for lauric acid content of VCO
is 45–56% [56–58], which is slightly higher than the value for
VCO in our study. It is important to note that the content of
active compounds varies between extraction and source of
VCO. The fatty acid content of VCO is strongly affected by
the temperature and humidity of the working environment
during production and by the source of the coconut; thus
the differences between our sample and the standard might
be due to external conditions such as source of the coconut,
mechanical forces, temperature during the production stage,
and the storage conditions of the VCO itself [59]. The first
and third most prevalent fatty acids (lauric acid and capric
acid, resp.) might be responsible for the effectiveness of VCO
treatment via the inhalation route as a rescue agent, as they
are known to have immunosuppression properties. Further
study to evaluate the effect of prominent active compounds
of VCO on allergic asthma model should be carried out.
Several studies reported that lauric acid has high antivi-
ral properties against lipid-coated RNA and DNA viruses,
antimicrobial activity against pathogenic Gram negative and
positive bacteria, antiprotozoal activity, and antifungal activ-
ity [60–62]. Capric acid (decanoic acid) also contributes to
the beneficial effect of VCO. It is mainly found in tropical
oils such as coconut oil, and the standard proportion in VCO
ranges from 4 to 8%. In our analysis it represented 5.17% of
the fatty acid content of the VCO. Capric acid and lauric acid
together represent powerful antioxidant and antimicrobial
components of coconut oil [60, 63]. Free fatty acids available
in this natural oil have been studied for their beneficial effects
on many aspects of health diseases. Various studies have
been done by scientists worldwide with some reporting that
VCO exhibits antibacteria [11], antiviruses, anti-HIV, anti-
inflammatory [40], and antidiabetes properties [16, 64] and
has been extensively used as topical application in treating
skin disorders [15, 65]. Study by Nurul-Iman et al. (2013)
showed that VCO is able to prevent blood pressure elevation
and improves endothelial function in rats [66]. The efficacy
and safety of the virgin coconut oil in reducing visceral
adiposity also have proved that VCO is efficacious as weight
reducing and safe for human consumption [16].
5. Conclusion
This study showed that VCO inhalation can alleviate inflam-
matory conditions of the airways following i.p. OVA treat-
ment and OVA inhalation in a rabbit model of allergic
asthma. The asthma features observed in this study were
found tomimic the human conditions of asthma.Our interest
was to evaluate the effectiveness of the VCO whether to act
as a rescue and/or a preventive agent in reducing symptoms
of allergic asthma. Our current study revealed that the VCO
inhalation reduced infiltration of proinflammatory cells,
especially eosinophils, into the airway cavity of the alveolar
spaces, which might be later used as an alternative treatment
for managing asthma conditions where the treatment was
found more effective as a rescue agent than as a preventive
agent. This might be due to the experimental design used
for the preventive group, in which rabbits were reexposed to
OVAvia inhalation ondays 28, 29, and 30 before sampleswere
collected. Lauric acid and capric acid were abundant in our
VCO sample, and they are known to have anti-inflammatory
properties. The combination of these fatty acids in the VCO
may explain the effectiveness of VCO inhalation in reducing
asthma-related symptoms. However, further study should be
carried out in order to confirmwhich specific compounds are
present in the VCO that contributes to the anti-inflammatory
effects as well as the possible molecular target which can
be served as specific treatment platform in the future. The
clinical study should be carefully planned in order to confirm
the effectiveness of VCO in treatment of patients.The current
study suggests the VCO inhalation might be a potential
complementary and alternative medication in managing
asthma patients.
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